However, the mutations were most prevalent in prostate, uterine, and bladder cancers (PRAD, UCEC, and BLCA, respectively), highlighting a potential link between GTF2E2 mutations and tumors of the urinogenital system. Here, GTF2E2 is linked to urinary bladder carcinoma.